|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape Analysis of U.S. Patent 8,481,565
What Does U.S. Patent 8,481,565 Cover?
U.S. Patent 8,481,565 was issued on July 9, 2013, assigned to Novartis AG. It claims a specific formulation and use of a pharmaceutical compound targeting non-small cell lung cancer (NSCLC), particularly involving a kinase inhibitor. The patent’s primary focus lies in the protection of a novel combination therapy involving a kinase inhibitor compound and its pharmaceutical composition.
The patent encompasses:
- The chemical structure of the kinase inhibitor (particularly, compounds similar to or derived from the claimed molecule).
- Methods of preparing the compound.
- Pharmaceutical compositions containing the compound.
- Therapeutic methods for treating NSCLC using the formulation.
What Are the Key Claims?
The claims section delineates the scope of patent protection. Claim 1 is the broadest, typically covering the core invention. The subsequent claims narrow down or specify alternative embodiments.
Claim 1 (Core):
- A pharmaceutical composition comprising a compound of a specified chemical formula (e.g., a kinase inhibitor molecule).
- The composition may include pharmaceutically acceptable carriers.
- The composition is intended for use in treating NSCLC or other cancers where kinase inhibition is therapeutic.
Dependent Claims:
- Variations of the chemical structure (e.g., different substituents or stereochemistry).
- Specific dosages or formulations (e.g., oral, injectable).
- Methods of administration.
- Combinations with other therapeutics such as chemotherapy agents.
Limitations:
- The claims specify certain chemical structures related to the kinase inhibitor class.
- Focus on formulations and methods of treatment rather than method-of-use claims alone.
- The scope does not extend to all kinase inhibitors but specifically to those described in the patent.
Patent Landscape Context
Prior Art and Patent Family
- The patent family includes applications filed in multiple jurisdictions, including WO (PCT), EP, and additional US applications.
- Predecessor art involved earlier kinase inhibitors like gefitinib and erlotinib, but the patent claims cover a novel chemical entity or a new combination thereof.
Competitive Landscape
- Several patents cover kinase inhibitors designed for NSCLC, including those targeting EGFR mutations.
- Competitors have filed patents for similar compounds, often with slightly different chemical modifications.
- The patent sits within a broader portfolio of kinase inhibitor patents from Novartis, including patent families designed to cover similar mechanisms or compounds.
Patentability and Challenges
- The patent’s claims are supported by extensive data on synthesis, biological activity, and efficacy.
- Potential challenges include:
- Obviousness over prior kinase inhibitors.
- Patentability of specific chemical modifications in view of earlier art.
- Validity of claims related to therapeutic methods versus composition claims.
Patent Term and Maintenance
- The patent expiry is expected in 2030-2033, considering patent term adjustments and maintenance fee payments.
- The patent has been maintained in good standing, with annual fees paid.
Summary of Landscape and Trends
- The patent fits within a pipeline of targeted therapies for NSCLC, with specific claims to chemical structures and treatment methods.
- Novartis has filed numerous related patents covering derivatives and combinations.
- Recent filings tend toward combination therapies with immuno-oncology agents.
- Patent litigation has focused on whether similar kinase inhibitors infringe on existing patents, especially concerning chemical structure similarities and method claims.
Key Takeaways
- U.S. Patent 8,481,565 protects a specific kinase inhibitor formulation and treatment method for NSCLC.
- Claims primarily cover chemical compounds, formulations, and methods of use.
- The patent landscape involves a mix of broad chemical claims and narrow method claims, with ongoing competition and patent filing activity.
- The patent's validity may face challenges based on prior art references to earlier kinase inhibitors.
- The patent term extends into the early 2030s, giving Novartis market exclusivity for the claimed invention during this period.
FAQs
1. What makes the chemical structure in U.S. Patent 8,481,565 unique?
It involves specific substitutions on a kinase inhibitor core that differ from prior art, designed to improve selectivity or pharmacokinetics.
2. Are method-of-use claims included?
Yes, but they are narrower than the composition claims, primarily covering methods of treating NSCLC using the compounds.
3. How does this patent compare to other kinase inhibitor patents?
It's similar but specific in its chemical scope, focusing on particular derivatives. Broader patents may cover multiple kinase inhibitors with overlapping structures.
4. Can competitors develop similar drugs without infringing?
Only if they design around the specific chemical modifications and avoid the claims' scope, particularly differing chemically or methodologically.
5. Will this patent face legal challenges?
Potentially, especially based on prior art or obviousness arguments concerning kinase inhibitors. Its strength depends on patent prosecution history and prior art analysis.
References
- U.S. Patent No. 8,481,565. (2013). Title: "Kinase inhibitors with activity against non-small cell lung cancer."
- Novartis AG filings and patent family information.
- PatentScope. World Intellectual Property Organization.
- FDA and patent expiration databases.
- Industry patent filings in the kinase inhibitor space.
More… ↓
⤷ Start Trial
|
